Histogen (Histogen) Valuation Rank

View and export this data going back to 2020. Start your Free Trial

What is Histogen Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Histogen Valuation Rank Related Terms

Thank you for viewing the detailed overview of Histogen's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Histogen (Histogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Histogen Inc (OTCPK:HSTO) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

10655 Sorrento Valley Road, Suite 200, San Diego, CA, USA, 92121

Website

https://www.histogen.com

Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.

Executives

Joyce Reyes	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Richard W Pascoe	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Rochelle Fuhrmann	director	C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Susan Richards Windham-bannister	director	78 BLANCHARD ROAD, BURLINGTON MA 01803
Moya Daniels	officer: See Remarks	10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Susan A. Knudson	officer: See Remarks	9191 TOWNE CENTRE DRIVE, SUITE 400, SAN DIEGO CA 92121
Jonathan Jackson	director, 10 percent owner	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Gail K Naughton	officer: See Remarks	C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Hugh Crean	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Stephen Chang	director	12912 CAMINO DEL VALLE, POWAY CA 92064
Brian Satz	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Yizhuo Zhang	director	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Martin Latterich	officer: See Remarks	C/O HISTOGEN INC., 10655 SORRENTO VALLEY ROAD, SUITE 200, SAN DIEGO CA 92121
Steven J Mento	director	C/O SANGAMO BIOSCIENCES, INC., 501 CANAL BLVD SUITE A-100, RICHMOND CA 94804
Keith W Marshall	officer: EVP, COO & CFO	C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127